pep08
MTAP-deleted Solid Tumors
PharmaEnginePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the MTAP-deleted Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bay 3713372 Bayer | Phase 1/2 | CC |
s095035 Servier Bio-Innovation LLC | Phase 1/2 | CC |
tng462 Servier Bio-Innovation LLC | Phase 1/2 | CC |
Same molecule, other indications
pep08 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →